CNSP Historical PE Ratio image   This CNSP PE ratio history page last updated 2/28/2023
CNSP PE History Chart
PeriodPriceGAAPTTMPE
Q3 2022
11/10/2022
5.58-2.70-10.50NA
Q2 2022
8/15/2022
7.77-2.70-12.00NA
Q1 2022
5/16/2022
8.52-2.10-13.80NA
Q4 2021
3/3/2022
10.95-3.00-16.20NA
Q3 2021
11/12/2021
36.90-4.20-18.60NA
Q2 2021
8/13/2021
50.10-4.50-18.00NA
Q1 2021
5/14/2021
53.70-4.50-18.00NA
Q4 2020
2/12/2021
103.20-5.40-17.10NA
Q3 2020
11/12/2020
66.60-3.60-16.80NA
Q2 2020
8/11/2020
54.90-4.50NANA
Q1 2020
5/15/2020
82.80-3.60NANA
Q4 2019
3/12/2020
66.30-5.10NANA
CNSP Historical PE Ratio Chart
PeriodPriceGAAPAnnualizedPE
Q3 2022
11/10/2022
5.58-2.70-10.80NA
Q2 2022
8/15/2022
7.77-2.70-10.80NA
Q1 2022
5/16/2022
8.52-2.10-8.40NA
Q4 2021
3/3/2022
10.95-3.00-12.00NA
Q3 2021
11/12/2021
36.90-4.20-16.80NA
Q2 2021
8/13/2021
50.10-4.50-18.00NA
Q1 2021
5/14/2021
53.70-4.50-18.00NA
Q4 2020
2/12/2021
103.20-5.40-21.60NA
Q3 2020
11/12/2020
66.60-3.60-14.40NA
Q2 2020
8/11/2020
54.90-4.50-18.00NA
Q1 2020
5/15/2020
82.80-3.60-14.40NA
Q4 2019
3/12/2020
66.30-5.10-20.40NA
Quotes delayed 20 minutes

Email EnvelopeFree CNSP Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
CNS Pharmaceuticals (CNSP) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

CNST PE Ratio History
CNTX PE Ratio History
CNVY PE Ratio History
COCP PE Ratio History
CODX PE Ratio History
COGT PE Ratio History
COLL PE Ratio History
COO PE Ratio History
CORT PE Ratio History
CPIX PE Ratio History
On this page we presented the CNSP PE Ratio History information for CNS Pharmaceuticals' stock. The average CNSP PE ratio history based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average CNSP PE ratio history based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this CNSP PE ratio history result, against the recent PE: when this page was posted on 2/27/2023, the most recent closing price for CNSP had been 1.60, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on CNSP or any other given stock, valuation analysis for CNSP can greatly benefit from studying the past earnings and resulting PE ratio history calculations. This type of study can help inform an analysis as to whether the earnings trajectory over time and current versus historical average PE ratios justify the current stock market value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate CNS Pharmaceuticals PE ratio history — or the PE history for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for next earnings dates and also historical earnings surprises history for CNSP. Thanks for visiting, and the next time you need to research CNSP PE Ratio History or the PE ratio history for another stock, we hope our site will come to mind as your go-to PE ratio history research resource of choice.

Recommended: RCD shares outstanding history, Dividend Aristocrats List, DEH Options Chain.

 

CNSP PE Ratio History | www.HistoricalPERatio.com | Copyright © 2020 - 2023, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.